
Opinion|Videos|December 9, 2024
Primary and Secondary Endpoints
Key Takeaways
Panelists discuss how the primary endpoint of the Effisayil 2 trial focused on the time to first GPP flare, while secondary endpoints assessed flare severity, quality of life, and inflammatory markers, providing a comprehensive evaluation of spesolimab's impact on GPP management.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
2
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
3
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
4
Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate
5












